CAS: 632-69-9; Acid Red 94, Indicator

相似化合物

632-69-9 16423-68-0 18472-87-2

上下游产品

CAS号4159-77-7 孟加拉红内酯 | CAS号24545-87-7 Spiro[isobenzof... | CAS号4159-77-7 孟加拉红内酯 | CAS号61738-01-0 玫瑰孟加拉双乙酸酯

专利信息

专利号:US-2022265691-A1
优先权日:2019-07-12
标 题 :Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
发明人：MAGNANI JOHN L; FOGLER WILLIAM E; THACKRAY HELEN M; FELDMAN ERIC J; STEWART DAVID
权利人:GLYCOMIMETICS INC
摘要:Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome. Interestingly, relapsed/refractory acute myeloid leukemia (AML) patients expressing high levels of sialyl Lex on their blasts show the greatest therapeutic response when treated with the E-selection inhibitor compound of Formula I. Transcriptome profiling of E-selectin ligand-forming glycosylation genes showed that ST3GAL4 and FUT7 were consistently expressed in the majority of cancers evaluated. Poor survival outcomes of FLT3-mutated AML patients that express high levels of ST3GAL4 and FUT7 implicated E-selectin in this disease state. These genes may be predictive biomarkers in AML patients. Methods of treatment of cancer comprising screening AML patients for expression of genes that contribute to the synthesis of the E-selectin ligand sialyl Lex, then treating those patients with an E-selection inhibitor, are disclosed.

专利号:US-7842826-B2
优先权日:2006-09-08
标题 :Process for synthesizing halogenated derivatives of fluorescein for use in the production of non-volatile memory devices
发明人：VOLPE MARIA VIVIANA; CIMMINO ANGELA; PEZZELLA ALESSANDRO; PALMA ANIELLO
权利人:ST MICROELECTRONICS SRL
摘要:A process performs solid phase synthesis of halogenated derivatives of fluorescein, and includes reacting fluorescein with a halide MX, wherein M is an alkali metal and X is a halogen, and Oxone® (2 KHSO 5 .KHSO 4 .K 2 SO 4 ), at a temperature higher than or equal to 150° C. A structure uses a halogenated derivative of fluorescein selected from the group consisting of 2′,4′,5′-trichlorofluorescein, 2′,4′,5′,7′-tetrachlorofluorescein, 4′,5′-diiodofluorescein diacetate and 2′,4′,5′-triiodofluorescein as electro-bistable material in a non-volatile memory device.

专利号:US-9422260-B2
优先权日:2009-09-18
标 题 :Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes
发明人：SINGER JAMIE; WACHTER ERIC A; SCOTT TIMOTHY; LUTZ MARLON; BABIAK KEVIN
权利人:PROVECTUS PHARMACEUTICALS INC; PROVECTUS PHARMATECH INC
摘要:A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.

专利号:US-9273022-B2
优先权日:2009-09-18
标 题:Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes
发明人：SINGER JAMIE; WACHTER ERIC A; SCOTT TIMOTHY; LUTZ MARLON; BABIAK KEVIN; DAMIREDDI SAHADEVA REDDY; DURRWACHTER J ROBERT
权利人:PROVECTUS PHARMACEUTICALS INC
摘要:A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.

专利号:US-2023097824-A1
优先权日:2020-05-08
标 题:Semi-synthesis and use of racemic hematoxylin
发明人：DURRANT EDWARD E; HEINDL DIETER; HUBER FLORIAN MAURITIUS ERASUMU; KLEIN ERIC; KOSMEDER II JEROME W; VOSS EDGAR
权利人:VENTANA MED SYST INC; ROCHE DIAGNOSTICS OPERATIONS INC
摘要:A racemic hematoxylin formulation is disclosed that includes one or both of a stabilizer compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process. Methods of using and making the stabilized composition also are disclosed.

专利号:WO-2024097977-A1
优先权日:2022-11-04
标题:Silk nanoparticle synthesis: tuning size, dispersity, and surface chemistry for drug delivery
发明人：SHAIDANI SAWNAZ; FALCUCCI THOMAS; FOSTER OLIVIA; SAHOO JUGAL KISHORE; HASTURK ONUR; KAPLAN DAVID L; JACOBUS CHARLOTTE S
权利人:TUFTS COLLEGE
摘要:Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-bearing solution and applying shear forces to the precipitate-bearing solution for a length of time sufficient to achieve evaporation of at least 95% of the volatile solvent, thereby producing a population of silk fibroin nanoparticles in water having a polydispersity index (PDI) of 0.35 or less, including but not limited to, a PDI of 0.330 or less, 0.325 or less, 0.315 or less, 0.310 or less, 0.30 or less, 0.275 or less, 0.250 or less, 0.225 or less, or 0.200 or less. Parameters related to silk fibroin molecular weight, silk fibroin concentration, shear force application, and temperature may all be modified to achieve silk nanoparticles of a particular size exhibiting particular PDIs.